Recombinant human erythropoietin beta therapy: An effective strategy to reduce transfusion requirement in children receiving anticancer treatment

Pediatric Hematology and Oncology

Volumn 25, Issue 6, 2008, Pages 509-521

  Çorapcioglu, Funda ^a   Aksu, Görkem ^a   Basar, Eviç Z ^a   Demirel, Atalay ^a   Öncel, Selim ^a   Mutlu, Ajda ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Anemia; Cancer; Children; Epoetin beta; Erythropoietin

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SUSPENSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; PROSPECTIVE STUDY;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 50249091071     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010802235132     Document Type: Article

References (38)

1. Voute PA. Introduction: managing anemia in pediatric cancer patients. Med Pediatr Oncol. 2002;39:446-447.
2. Michon J. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey. Med Pediatr Oncol. 2002;39:448-450.
3. Ruggiero A, Riccardi R. Interventions for anemi in pediatric cancer patients. Med Pediatr Oncol. 2002;39:451-454.
4. Feusner J, Hastings C. Recombinant human erytropoetin in pediatric oncology: a review. Med Pediatr Oncol. 2002;39:463-468.
5. Boogaerts M, Oberhoff C, Bokkel Huinink WT, et al. Epoetin beta (NeoRecormon®) therapy in patients with solid tumors receiving platinum and non-platinum chemotherapy: a meta analysis. Anticancer Res. 2006;26:479-484.
6. Ross SD, Allen E, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006;28:801-831.
7. Pronzato P, Jassem J, Mayordomo J. Epoetin beta therapy in patients with solid tumors. Crit Rev Oncol Hematol. 2006;58:46-52.
8. Pujade Lauraine E, Richard AJ, Sapede C, Hayward C. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin α, epoetin ß and darbepoetin α use in routine clinical practice. Oncol Rep. 2005;14:1037-1044.
9. Moréré JF. Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer. 2004;46:149-156.
10. Varan A, Büyükpamukçu M, Kutluk T, Akyüz C. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children. Pediatrics. 1999;103:E16.
11. MacMillian ML, Freedman MH. Recombinant human erythropoietin in children with cancer. J Pediatr Hematol Oncol. 1998;20:187-189.
12. Zoubek A, Kronberger M. Early epoetin alfa treatment in children with solid tumor. Med Pediatr Oncol. 2002;39:459-462.
13. Yilmaz D, Çetingül N, Kantar M, et al. A single institutional experience: is epoetin alpha effective in anemic children with cancer. Pediatr Hematol Oncol. 2004;21:1-8.
14. Léon P, Jiménez M, Barona P, Sierrasesǔmaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol. 1998;30:110-116.
15. Porter JC, Leahey A, Polise K, et al. Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: a randomized, double-blind, placebo-controlled trial. J Pediatr. 1996;129:656-660.
16. Wagner LM, Billups CA, Furman WL, et al. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial. J Clin Oncol. 2004;22:1886-1893.
17. Kronberger M, Fischmeister G, Poetschger U, Gadner H, Zoubek A. Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a case-control study. Pediatr Hematol Oncol. 2002;19:95-105.
18. Büyükpamukçu M, Varan A, Kutluk T, Akyüz C. Is epoetin alfa a treatment oftion for chemotherapy-related anemia in children. Med Pediatr Oncol. 2002;39:455-458.
19. Csāki C, Ferencz T, Schuler D, Borsi JD. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer. 1998;34:364-367.
20. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43:258-270.
21. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiation Oncol Biol Phys. 2001;50:705-715.
22. Van Belle SJP, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol. 2003;47:1-11.
23. Caro J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer. 2001;91:2214-2221.
24. Coiffier B. Epoetin once weekly in anaemic patients with cancer. Br J Haematol. 2004;125:100-101.
25. Razzouk BI, Hord JD, Hockenberry M, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. J Clin Oncol. 2006;24:3583-3589.
26. Kawaguchi T, Moriyama T, Suzuki K, et al. Pilot study of the optimum mematocrit for patients in the predialysis stage after renal transplantation. Transplant Proc. 2004;36:1293-1296.
27. Rachmilewitz EA, Aker M, Perry D, Dover G. Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous betathalassaemia. Br J Haematol. 1995;90:341-345.
28. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2004;40:2201-2216.
29. Bolonaki I, Stiakaki E, Lydaki E, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol. 1996;13:111-121.
30. Baron F, Sautois B, Baudoux E, et al. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2002;30:546-554.
31. Rothmann SA, Paul P, Weick JK, McIntyre WR, Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning. 1985;3:415-423.
32. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322:1689-1692.
33. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995;76:2319-2329.
34. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;193:CD003407.
35. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-220.
36. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2006;24:4708-4713.
37. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032.
38. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.